



PATENT  
ATTORNEY DOCKET NO.: TNX 98-4  
CUSTOMER NO: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re the Application of:**  
**MELIEF, Cornelis, et al.**

**Serial No.: 09/316,935**

**Filed: May 22, 1999**

**For: CD40 BINDING MOLECULES AND CTL  
PEPTIDES FOR TREATING TUMORS**

Group Art Unit: 1632

**Examiner: A. Beckerleg**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**Dear Sir:**

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants submit the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b), but before the mailing of either a Final Office Action, Quayle Action, or Notice of Allowance. Please charge the fee of \$180.00 for consideration of this Information Disclosure Statement to our Deposit Account No. 20-0087.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached PTO 1449 form.

This submission does not represent that a search has been made or that no other documents exist which may be material to the examination of this application and does not constitute an admission that any of the listed documents, or any part thereof,

are material or constitute prior art under title 35 of the United States code. Applicants reserve the right to present evidence that any of such documents are not prior art.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


Respectfully Submitted,

Dated: April 3, 2001.

BY: Cheryl A. Liljestrand  
Cheryl A. Liljestrand  
Reg. No. 45,275

Mailing Address:

Tanox, Inc.  
10301 Stella Link  
Houston, TX 77025  
(713) 578-4000



Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET  OF

## Complete if Known

Application Number	09/316,935
Filing Date	MAY 22, 1999
First Named Inventor	MELIEF, ET AL
Group Art Unit	1632
Examiner Name	A. BECKERLEG
Attorney Docket Number	98-4

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
	5874082		DE BOER	02-23-1999	

## FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents				Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)					
	PCT	97/41440	A 1		VAN DER BURG ET AL.	11-06-1997		N/A

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

2

OF

2

### Complete if Known

Application Number 09/316,935  
Filing Date MAY 22, 1999  
First Named Inventor MELIEF, ET AL  
Group Art Unit 1632  
Examiner Name A. BECKERLEG

Attorney Docket Number 98-4

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s),	T 2
	C1	Lipford, G. B., et al.; "Peptide Engineering Allows Cytotoxic T-Cell Vaccination Against Human Papiloma Virus Tumour Antigen, E6", <i>Immunology</i> 84:298-303 (1995).	
	C2	Christ, M., et al., "Gene Therapy With Recombinant Adenovirus Vectors: Evaluation of the Host Immune Response", <i>Immunology Letters</i> , 57:19-25 (1997).	
	C3	Naviaux, R. et al.; "Retroviral Vectors For Persistent Expression <i>In Vivo</i> ", <i>Current Opinion in Biotechnology</i> 3:540-547 (1992).	
	C4	Gunzburg, W. H. et al.; "Virus Vector Design In Gene Therapy", <i>Molecular medicine today</i> , Vol. 1(9), pp. 410-417 (1995).	
	C5	Urvanelli, D., et al., "C-Terminal Domain Of The Adenovirus E1A Oncogene Product Is Required For Induction of Cytotoxic T Lymphocytes And Tumor-Specific Transplantation Immunity", <i>Virology</i> 173:607-614 (1989).	
	C6	Funakoshi, D., et al.; "Inhibition Of Human B-Cell Lymphoma Growth By CD40 Stimulation", <i>Blood</i> , Vol. 83(10), pp. 2797-2798 (1994).	
	C7	Tong, Alex. W. Et Al; "Anti-CD40 Antibody Binding Modulates Human Multiple Myeloma Clonogenicity In Vitro", <i>Blood</i> , Vol. 84(9), pp. 3026-3033 (1994).	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line  
through citation if not in conformance and not considered. Include copy of this form with next communication to  
applicant.